## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($1020.83)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Eli Lilly & Company (LLY): Buyers looking for rally between $1144.4 â€“ $1196.17**
- Source: FXStreet | 20251223T135214 | Bullish | Relevance: 100%
- Eli Lilly & Company (LLY) is expected to rally between $1144.39 and $1196.17, following its impulse wave I within the larger August-2025 rally. The Elliott Wave analysis indicates an ongoing bullish impulse sequence, with the stock trading at an All-Time High. Buyers are advised to look for pullbacks in clear 3, 7, or 11 swings corrections before resuming upside movement.

**2. Jim Cramer Says Eli Lilly's GLP-1 Pill Is "Going to Revolutionize Everything"**
- Source: Finviz | 20251223T052843 | Bullish | Relevance: 100%
- Jim Cramer highlighted Eli Lilly and Company (LLY) as a powerful drug company set to revolutionize the market with its GLP-1 pill form next year, predicting a significant stock increase. He also analyzed other top holdings of a caller, including Taiwan Semi, Microsoft, Chevron, and SL Green, offering his assessment of their diversification and potential. Cramer expressed optimism about Eli Lilly's future performance, while providing a balanced view of the other companies in the portfolio.

**3. Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment**
- Source: Finviz | 20251222T083900 | Bullish | Relevance: 100%
- Eli Lilly and Company (LLY) announced updated data for its oral estrogen receptor antagonist Inluriyo, showing a 38% reduction in the risk of progression or death for advanced or metastatic breast cancer as a monotherapy. The company also revealed plans to offer single-dose vials of Zepbound at reduced prices due to an agreement with the Trump administration aimed at lowering GLP-1 medication costs. Goldman Sachs recently raised its price target for Eli Lilly to $1,145 from $951, reiterating a Buy rating on the stock.

**4. These Stocks Moved the Most Today: Novo Nordisk, ServiceNow, Micron, DJT, Freeport-McMoRan, Zim, and More**
- Source: Barron's | 20251223T210840 | Neutral | Relevance: 100%
- The S&P 500 closed at a record high on Tuesday after the release of stronger-than-expected third-quarter GDP figures for the U.S. economy. This article highlights several stocks that experienced significant movement, including Novo Nordisk, ServiceNow, Micron, DJT, Freeport-McMoRan, and Zim.

**5. These Stocks Are Moving the Most Today: Novo Nordisk, Eli Lilly, Huntington Ingalls, Micron, DJT, Zim, and More**
- Source: Barron's | 20251223T120812 | Neutral | Relevance: 100%
- This article highlights several stocks that are experiencing significant movement today, including Novo Nordisk, Eli Lilly, Huntington Ingalls, Micron, DJT, and Zim. The market experienced mixed stock futures trading on Tuesday, influenced by upcoming U.S. GDP data and consumer confidence readings.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $1268 | $1286 | -1% |
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($1.49M) |
| Sells | 28 ($18559.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.1% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $18559M sold (28 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.99 indicates undervaluation relative to growth. Forward P/E 33.1x attractive for 38% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Analyst sentiment positive (4 raises, avg +12%). Insider selling cluster ($18559.1M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $965.5B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.99 |
| Forward P/E | 33.1 |
| Current P/E | 45.5 |
| YoY Growth | 37.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 4.5% to 0.5% (-4.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.5pp (needs >3.0% for momentum thesis). MRS_5 (-0.5%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.47% (CS: 81) | Neutral |
| RSI_14 | 64.0 | Neutral |
| MACD Histogram | -0.21 | Bearish |
| vs SMA20 | 1.032x | Above |
| vs SMA50 | 1.108x | Above |
| vs SMA200 | 1.310x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $1076.07
- **Stop Loss:** $1020.83 (5.1% risk)
- **Target:** $1131.31 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 21
- **Position Value:** $22,597.47
- **Portfolio %:** 22.60%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*